Through computer analysis, Mallick et al. identified the key TrkA-binding peptide sequence of NGF and designed a hybrid peptide candidate that blocks the interaction between NGF and TrkA, which showed potential in the treatment of ameloblastoma [176]. The gene discussed is NTRK1; the disease is ameloblastoma.